We read with great interest the practice guidelines for the diagnosis and management of autoimmune hepatitis recently issued by the American Association for the Study of Liver Diseases (AASLD). 1 In particular, we appreciate the new definition of biochemical remission, which now requires not only no
Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection
β Scribed by Jason Grebely; Kathy Petoumenos; Margaret Hellard; Gail V. Matthews; Vijayaprakash Suppiah; Tanya Applegate; Barbara Yeung; Phillipa Marks; William Rawlinson; Andrew R. Lloyd; David Booth; John M. Kaldor; Jacob George; Gregory J. Dore
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 263 KB
- Volume
- 52
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
Polymorphisms in the IL28B (interleukin-28B) gene region are important in predicting outcome following therapy for chronic hepatitis C virus (HCV) infection. We evaluated the role of IL28B in spontaneous and treatment-induced clearance following recent HCV infection. The Australian Trial in Acute Hepatitis C (ATAHC) was a study of the natural history and treatment of recent HCV, as defined by positive anti-HCV antibody, preceded by either acute clinical HCV infection within the prior 12 months or seroconversion within the prior 24 months. Factors associated with spontaneous and treatment-induced HCV clearance, including variations in IL28B, were assessed. Among 163 participants, 132 were untreated (n = 52) or had persistent infection (infection duration β₯26 weeks) at treatment initiation (n = 80). Spontaneous clearance was observed in 23% (30 of 132 participants). In Cox proportional hazards analysis (without IL28B), HCV seroconversion illness with jaundice was the only factor predicting spontaneous clearance (adjusted hazards ratio = 2.86; 95% confidence interval = 1.24, 6.59; P = 0.014). Among participants with IL28B genotyping (n = 102 of 163 overall and 79 of 132 for the spontaneous clearance population), rs8099917 TT homozygosity (versus GT/GG) was the only factor independently predicting time to spontaneous clearance (adjusted hazard ratio = 3.78; 95% confidence interval = 1.04, 13.76; P = 0.044). Participants with seroconversion illness with jaundice were more frequently rs8099917 TT homozygotes than other (GG/GT) genotypes (32% versus 5%, P = 0.047). Among participants adherent to treatment and who had IL28B genotyping (n = 54), sustained virologic response was similar among TT homozygotes (18 of 29 participants, 62%) and those with GG/GT genotype (16 of 25, 64%, P = 0.884).
Conclusion:
During recent hcv infection, genetic variations in il28b region were associated with spontaneous but not treatment-induced clearance. early therapeutic intervention could be recommended for individuals with unfavorable il28b genotypes.
π SIMILAR VOLUMES
Polymorphisms near the IL28B gene, which code for interferon (IFN)-Ξ»3, predict response to pegylated interferon-Ξ± (PEG-IFN) and ribavirin treatment in hepatitis C virus (HCV) genotype 1 infected patients. Follow-up studies of the effect of IL28B gene in HCV non-genotype 1 infected patients have almo
Polymorphism in the interleukin-28B (IL28B) gene region, encoding interferon (IFN)-k3, is strongly predictive of response to antiviral treatment in the nontransplant setting. We sought to determine the prevalence and impact on clinical outcomes of donor and recipient IL28B genotypes among liver tran
We read with great interest the recent report by Li et al. 1 analyzing the correlation between the clusters of differentiation 24 (CD24) polymorphism and risk of chronic hepatitis B virus (HBV) infection. In their study, the CD24 P170 T allele (thymidine at position 170) was correlated with a strong
## Abstract An investigation was carried out to determine whether early viral monitoring could predict efficiently the virological response to combination therapy of two different regimens in treatmentβnaΓ―ve chronic hepatitis C patients infected with genotype 1b with high baseline viral load. Patie